This report concerns a female patient with B-precursor acute lymphoblastic leukemia with concomitant expression of CD13 and CD33. A rare chromosomal abnormality, t(2;17)(p13:q21), was detected in 70% of metaphases analyzed. A new subgroup of acute leukemia is proposed, consisting of our case and 12 reported cases with similar chromosomal abnormalities. This subgroup has a poor prognosis and a high incidence of biphenotypic characteristics.
To evaluate the specific reactivity of HLA Class I antibodies (HLA‐I Abs) in acute non‐hemolytic transfusion reactions (ANHTRs) using solid phase assays (SPAs) and conventional complement‐dependent lymphocyte cytotoxicity test (LCT). ANHTRs are major issues in transfusion medicine. Anti‐leukocyte antibodies have been implicated as one of the causative agents of transfusion‐related acute lung injury (TRALI) and febrile reaction. Antibodies to HLA Class I and/or Class II (HLA Abs) have been intensively studied using SPAs for TRALI, but not for febrile reaction. About 107 patients and 186 donors associated with ANHTRs were screened for HLA Abs by SPAs such as enzyme‐linked immunosorbent assay (ELISA) and the Luminex method. When HLA‐I Ab was detected, its specific reactivity was evaluated by comparing its specificity identified by the Luminex method using recombinant HLA molecules and cognate HLA antigens (Ags), as well as LCT with or without anti‐human globulin (AHG). The incidences of HLA Abs were as high as 32·7% of patients' serum samples and 16% of donors' serum samples. The incidence of HLA‐I Abs did not differ significantly between cases of febrile and allergic reactions. However, HLA‐I Abs associated with febrile reaction showed a significantly higher rate of possessing specific reactivity to cognate HLA Ags than those associated with allergic reactions. In addition, the Luminex method enabled the detection of HLA‐I Abs much earlier than AHG‐LCT in serum samples from a patient with febrile reaction and platelet transfusion refractoriness (PTR). SPAs seem more useful than AHG‐LCT for evaluating reactivity of antibodies in ANHTR cases.
We report the case of a 61-year-old man with pyoderma gangrenosum (PG) who was successfully treated with high-dose intravenous immunoglobulin (IVIg). He was transported to hospital with fever, pain and ulcer of the left inner thigh, and pancytopenia. PG associated with myelodysplastic syndrome was diagnosed, and treatment with methyl-prednisolone at 1.0 g/day for 3 days was followed by oral prednisolone. As the ulcer deteriorated when prednisolone dose was reduced, he was admitted to our hospital. IVIg was administered twice, with high fever promptly subsiding and the ulcer markedly decreasing in size. IVIg may represent a good option when steroid therapy proves insufficient.
30 March 2004 in Clinical and Laboratory Haematology
A quantitative nested reverse transcriptase polymerase chain reaction (QN‐RT‐PCR) method was developed using a plasmid cDNA containing the AML1/ETO (MTG8) fusion transcript from Kasumi‐1 cells, an acute‐myelogenous leukemia cell line with the t(8;21) translocation. In this method, the plasmid was detectable at a concentration of 10−17 m. The fusion transcript in a mixture of 107 Rice94 (Burkitt lymphoma cell line) cells containing two Kasumi‐1 cells was detectable at 10−17 m. In a previously published real‐time PCR method, the plasmid containing the fusion transcript was detectable at 10−16 m or higher, and 20 or more Kasumi‐1 cells were detectable in 107 Rice94 cells. Thus, this QN‐RT‐PCR method is more sensitive than the real‐time PCR. When the same samples were examined by real‐time PCR and our QN‐RT‐PCR method, in one patient in clinical remission after chemotherapy and allogeneic‐bone marrow transplantation (BMT), the transcript was detected by QN‐RT‐PCR 60 days prior to hematological relapse, in contrast to 10 days before hematological relapse by real‐time PCR. The transcript level was below 10−17 m (undetectable) with this QN‐RT‐PCR in patients in clinical remission after chemotherapy and BMT, while it was 10−15–10−16 m in patients in clinical remission after chemotherapy alone. The quantitative difference of the transcript level in minimal residual disease (MRD) between these two different types of clinical remission was estimated to be at least 102‐fold. This QN‐RT‐PCR method is useful for predicting hematological relapse and for quantitatively estimating MRD in different types of clinical remission.